Acute lymphocytic leukaemia refractory

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase I: 2 Phase I (First in Human): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase I

2 trials
  • Iovance Biotherapeutics Inc. Commercial
    IMP not specified
    2023-509132-26-00 2 countries 2025 n=16
    Ended
  • Institut Paoli Calmettes Academic
    IMP not specified
    2024-518265-10-01 1 country 2020 n=24
    Ended

Phase I (First in Human)

1 trial
  • AstraZeneca AB Commercial
    AZD3632
    2025-521299-76-00 3 countries 2025 n=17
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Iovance Biotherapeutics Inc. Commercial 1 Phase I 0
AstraZeneca AB Commercial 1 Phase I (First in Human) 1
Institut Paoli Calmettes Academic 1 Phase I 0
New trials by year
2020
1
2025
2
← All indication landscapes